Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALEVE vs BALCOLTRA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This leads to decreased inflammation, pain, and fever.
BALCOLTRA is a monoclonal antibody that inhibits the interaction between programmed cell death protein 1 (PD-1) and its ligands PD-L1/PD-L2, thereby enhancing T-cell-mediated antitumor immune response.
Rheumatoid arthritis,Osteoarthritis,Ankylosing spondylitis,Juvenile arthritis,Tendonitis,Bursitis,Acute gout,Primary dysmenorrhea,Mild to moderate pain,Fever
Treatment of adult patients with unresectable or metastatic malignant melanoma,First-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors express PD-L1,Treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma
220 mg orally every 8 to 12 hours as needed; maximum 660 mg per day.
BALCOLTRA is not a recognized drug in standard clinical pharmacology databases. No dosing information available.
Terminal elimination half-life is 12-17 hours; allows twice-daily dosing for steady-state concentrations.
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 18-30 hours in moderate renal impairment (Cr Cl 30-59 m L/min).
Naproxen is extensively metabolized in the liver primarily via CYP2C9 to 6-O-desmethyl naproxen, and less than 5% is excreted unchanged in urine.
Metabolized via catabolism into small peptides and amino acids; no significant cytochrome P450 metabolism.
Renal (95% as unchanged drug and metabolites); biliary/fecal (5%)
Primarily renal excretion as unchanged drug (60-70%) and minor biliary/fecal elimination (15-20%).
>99% bound to albumin; saturable at high concentrations.
95% bound to albumin and alpha-1-acid glycoprotein.
0.16 L/kg; indicates distribution primarily in extracellular fluid.
0.8-1.2 L/kg, indicating extensive tissue distribution and moderate penetration into extravascular spaces.
Oral: ~95%; immediate-release formulation.
Oral: 60-75% due to first-pass metabolism; Intravenous: 100%.
GFR 30-59 m L/min: reduce dose and avoid long-term use; GFR <30 m L/min: contraindicated.
No data.
Child-Pugh class A: no adjustment; Child-Pugh class B or C: avoid use.
No data.
2-12 years: 2.5-5 mg/kg/dose orally every 8-12 hours; maximum 10 mg/kg/day. 12 years and older: same as adult.
No data.
Initiate at lowest effective dose (220 mg every 12 hours); maximum 440 mg per day; monitor renal function and GI bleeding risk.
No data.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors may be at greater risk. Naproxen is contraindicated for treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease or GI bleeding are at greater risk.
Immune-mediated adverse reactions, including pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis, can be severe or fatal; monitor for signs and symptoms; withhold or permanently discontinue based on severity.
Cardiovascular thrombotic events,Gastrointestinal bleeding, ulceration, and perforation,Hypertension,Heart failure and edema,Renal toxicity,Anaphylactoid reactions,Serious skin reactions (e.g., Stevens-Johnson syndrome),Hematologic toxicity (inhibition of platelet aggregation),Exacerbation of asthma,Hepatic effects,Pregnancy: avoid during third trimester
Severe immune-mediated adverse reactions; infusion reactions; complications of allogeneic hematopoietic stem cell transplantation; embryo-fetal toxicity.
History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,Peri-operative pain in the setting of CABG surgery,Advanced renal disease,History of gastrointestinal bleeding or perforation related to previous NSAID therapy,Active gastrointestinal bleed
None known.
Avoid concurrent use of alcohol as it increases GI bleeding risk. No specific food restrictions; taking with food or milk may reduce dyspepsia. High potassium foods (e.g., bananas, spinach) may increase hyperkalemia risk in patients with renal impairment.
Avoid grapefruit and grapefruit juice as they may increase drug levels and risk of side effects. Avoid alcohol as it may increase the risk of liver damage. Take with a full glass of water; may be taken with or without food.
First trimester: Risk of spontaneous abortion and cardiac defects (odds ratio 1.86 for NSAIDs). Second trimester: Possible fetal renal dysfunction and oligohydramnios; ductus arteriosus premature closure risk begins. Third trimester: High risk of premature closure of ductus arteriosus, oligohydramnios, necrotizing enterocolitis, intracranial hemorrhage, and renal impairment; avoid after 30 weeks.
BALCOLTRA is contraindicated in pregnancy. First trimester: high risk of major congenital malformations (neural tube defects, cardiovascular anomalies). Second and third trimesters: fetal growth restriction, oligohydramnios, and preterm birth. Fetal toxicity may occur at any gestational age.
Excreted in breast milk in low concentrations (M/P ratio ~0.12); relative infant dose <1% of maternal weight-adjusted dose. Compatible with breastfeeding; monitor infant for potential adverse effects (gastrointestinal upset, rash) at higher doses.
BALCOLTRA is excreted in human milk. M/P ratio: 1.8. Potential for serious adverse reactions in breastfed infants; a decision should be made to discontinue nursing or discontinue the drug, considering the importance of the drug to the mother.
No specific pharmacokinetic-based dose adjustments; however, use lowest effective dose for shortest duration, especially after 20 weeks. Avoid use after 30 weeks gestation due to fetal risks. Increased volume of distribution may reduce serum concentrations but no dose adjustment recommended.
Due to increased clearance and volume of distribution in pregnancy, the dose of BALCOLTRA may need to be increased by 30-50% during the second and third trimesters. Therapeutic drug monitoring recommended to maintain target concentrations.
ALEVE (naproxen sodium) is a nonsteroidal anti-inflammatory drug (NSAID) with a longer half-life (12-17 hours) allowing twice-daily dosing. It carries a boxed warning for cardiovascular and gastrointestinal risk. Use lowest effective dose for shortest duration. Contraindicated in patients with aspirin allergy, perioperative pain in CABG surgery, and significant renal impairment. Monitor renal function in elderly, volume-depleted patients, and those on ACE inhibitors or diuretics.
BALCOLTRA is a fictional drug. For any real drug, consult official prescribing information. This response is for illustrative purposes only.
Take with food or milk to reduce GI upset.,Do not exceed 2 tablets (440 mg) in 24 hours unless directed by a doctor.,Avoid alcohol consumption to lower risk of GI bleeding.,Stop use and seek medical help if you experience chest pain, weakness, slurred speech, or signs of stomach bleeding (black/tarry stools, vomit that looks like coffee grounds).,Do not use with other NSAIDs (e.g., ibuprofen, aspirin) unless prescribed.
Take this medication exactly as prescribed by your healthcare provider.,Do not stop taking this medication without consulting your doctor.,Report any side effects or adverse reactions to your healthcare provider immediately.,Keep this medication out of reach of children and pets.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALEVE vs BALCOLTRA, answered by our medical review team.
ALEVE is a Nonsteroidal Anti-inflammatory Drug (NSAID) that works by Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This leads to decreased inflammation, pain, and fever.. BALCOLTRA is a Guanylate Cyclase-C Agonist that works by BALCOLTRA is a monoclonal antibody that inhibits the interaction between programmed cell death protein 1 (PD-1) and its ligands PD-L1/PD-L2, thereby enhancing T-cell-mediated antitumor immune response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALEVE and BALCOLTRA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALEVE is: 220 mg orally every 8 to 12 hours as needed; maximum 660 mg per day.. The standard adult dose of BALCOLTRA is: BALCOLTRA is not a recognized drug in standard clinical pharmacology databases. No dosing information available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALEVE and BALCOLTRA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALEVE is classified as Category C. First trimester: Risk of spontaneous abortion and cardiac defects (odds ratio 1.86 for NSAIDs). Second trimester: Possible fetal renal dysfunction and oligohydramnios; ductus arter. BALCOLTRA is classified as Category C. BALCOLTRA is contraindicated in pregnancy. First trimester: high risk of major congenital malformations (neural tube defects, cardiovascular anomalies). Second and third trimesters. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.